Clinical Trial Search

Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001

Primary: Responder Rate of B-Cell Depletion at Week 4 — 87.5; 100.0; 87.5; 100.0 percentage of participants

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Safety and Tolerability — 10; 9; 10; 9 Participants with at least one TEAE

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Safety and Tolerability — 21; 22 participants

Primary: Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening…

Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003

Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384

Primary: Cumulative Number of New Gadolinium-enhancing (GdE) T1 Lesions at Week 12 — 4.2; 1.7; 2.2; 2.2 Cumulative number of lesions — p=<0.001

Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects

Primary: Time to First Relapse — 332.0; 290.0; 495.0; 432.0 days — p=0.643

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period — 0.290; 0.155 relapses/participant year of…

Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…

Primary: Annualized Relapse Rate [ARR]: Poisson Regression Estimates — 0.539; 0.370; 0.369 relapses per year — p=0.0005

Primary: Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. — 45 participants

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks — 0.292; 0.156 relapses/participant year of treatment — p=<0.0001

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001

Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions

Primary: Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6 — 22.5; 3.5 units on a scale

Primary: Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions — 1.03; 1.39; 0.77; 0.76 lesions — p=0.1673

Primary: Estimated Annualized Aggregate Relapse Rate (ARR) — 0.16; 0.18; 0.40 Relapses per year

Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: The Primary Outcome Measure is the Number of "Combined Active Lesions" (CAL) by Monthly MRI at the Conclusion of the Study. — 0.63; 0.58 Average number of lesions per…

Primary: Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL) — 0.51; 0.83; 7.46 mg

Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001

Primary: ARR - PDEs — 0.12; 0.16; 0.11 relapses per year